De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

NCT06001320 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplant; Complications
CMV

Interventions

DRUG: Letermovir 480 mg once daily
OTHER: Historical/Control

Sponsor

Virginia Commonwealth University

Collaborators

[object Object]